Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. It has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The Company is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others.
Símbolo de cotizaciónXAIR
Nombre de la empresaBeyond Air Inc
Fecha de salida a bolsaMay 07, 2019
Director ejecutivoLisi (Steven A)
Número de empleados61
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 07
Dirección900 Stewart Ave
CiudadGARDEN CITY
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal11530
Teléfono15166658200
Sitio Webhttps://www.beyondair.net/
Símbolo de cotizaciónXAIR
Fecha de salida a bolsaMay 07, 2019
Director ejecutivoLisi (Steven A)
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos